These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
480 related articles for article (PubMed ID: 19911855)
1. Valsartan: more than a decade of experience. Black HR; Bailey J; Zappe D; Samuel R Drugs; 2009; 69(17):2393-414. PubMed ID: 19911855 [TBL] [Abstract][Full Text] [Related]
2. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis. Chrysant SG; Murray AV; Hoppe UC; Dattani D; Patel S; Hsu H; Zhang J Curr Med Res Opin; 2008 Apr; 24(4):1039-47. PubMed ID: 18307835 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306 [TBL] [Abstract][Full Text] [Related]
4. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option. Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075 [TBL] [Abstract][Full Text] [Related]
5. Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide 25 mg once daily for the treatment of hypertension. White WB; Punzi HA; Murwin D; Koval SE; Davidai G; Neutel JM J Clin Hypertens (Greenwich); 2006 Sep; 8(9):626-33. PubMed ID: 16957424 [TBL] [Abstract][Full Text] [Related]
6. Combination therapy versus monotherapy as initial treatment for stage 2 hypertension: a prespecified subgroup analysis of a community-based, randomized, open-label trial. Everett BM; Glynn RJ; Danielson E; Ridker PM; Clin Ther; 2008 Apr; 30(4):661-72. PubMed ID: 18498915 [TBL] [Abstract][Full Text] [Related]
7. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. Black HR; Graff A; Shute D; Stoltz R; Ruff D; Levine J; Shi Y; Mallows S J Hum Hypertens; 1997 Aug; 11(8):483-9. PubMed ID: 9322828 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan. da Silva PM Clin Drug Investig; 2010; 30(9):625-41. PubMed ID: 20626210 [TBL] [Abstract][Full Text] [Related]
9. Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups. Assaad-Khalil SH; Najem R; Sison J; Kitchlew AR; Cho B; Ueng KC; DiTommaso S; Shete A Vasc Health Risk Manag; 2015; 11():71-8. PubMed ID: 25653536 [TBL] [Abstract][Full Text] [Related]
10. Randomized study to compare valsartan +/- HCTZ versus amlodipine +/- HCTZ strategies to maximize blood pressure control. Zappe D; Papst CC; Ferber P; Vasc Health Risk Manag; 2009; 5():883-92. PubMed ID: 19898644 [TBL] [Abstract][Full Text] [Related]
11. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations. Bobrie G; Delonca J; Moulin C; Giacomino A; Postel-Vinay N; Asmar R; Am J Hypertens; 2005 Nov; 18(11):1482-8. PubMed ID: 16280286 [TBL] [Abstract][Full Text] [Related]
12. Chronotherapy with valsartan/hydrochlorothiazide combination in essential hypertension: improved sleep-time blood pressure control with bedtime dosing. Hermida RC; Ayala DE; Mojón A; Fontao MJ; Fernández JR Chronobiol Int; 2011 Aug; 28(7):601-10. PubMed ID: 21823969 [TBL] [Abstract][Full Text] [Related]
13. Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study. Sharma AM; Davidson J; Koval S; Lacourcière Y Cardiovasc Diabetol; 2007 Oct; 6():28. PubMed ID: 17910747 [TBL] [Abstract][Full Text] [Related]
14. Valsartan/hydrochlorothiazide: a review of its pharmacology, therapeutic efficacy and place in the management of hypertension. Wellington K; Faulds DM Drugs; 2002; 62(13):1983-2005. PubMed ID: 12215069 [TBL] [Abstract][Full Text] [Related]
15. Combination therapy with valsartan/hydrochlorothiazide at doses up to 320/25 mg improves blood pressure levels in patients with hypertension inadequately controlled by valsartan 320 mg monotherapy. Tuomilehto J; Tykarski A; Baumgart P; Reimund B; Le Breton S; Ferber P Blood Press Suppl; 2008 Jun; 1():15-23. PubMed ID: 18705531 [TBL] [Abstract][Full Text] [Related]
16. Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone. Waeber B; Aschwanden R; Sadecky L; Ferber P J Hypertens; 2001 Nov; 19(11):2097-104. PubMed ID: 11677377 [TBL] [Abstract][Full Text] [Related]
17. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension. Calhoun DA; Glazer RD; Pettyjohn FS; Coenen PD; Zhao Y; Grosso A Curr Med Res Opin; 2008 Aug; 24(8):2303-11. PubMed ID: 18593517 [TBL] [Abstract][Full Text] [Related]
19. Impact of angiotensin receptor blockade in combination with hydrochlorothiazide 25 mg in 2121 patients with stage 1-2 hypertension. White WB; Davidai G; Schumacher H J Hum Hypertens; 2009 Dec; 23(12):817-25. PubMed ID: 19357698 [TBL] [Abstract][Full Text] [Related]
20. The role of baseline blood pressure in guiding treatment choice: a secondary analysis of the use of valsartan/hydrochlorothiazide as initial therapy in hypertensive adults in a randomized, double-blind, placebo-controlled trial. Pool JL; Glazer R; Crikelair N; Levy D Clin Drug Investig; 2009; 29(12):791-802. PubMed ID: 19888785 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]